It is also possible to deliver melanoma tumor antigens (MelA, GP100) specifically to cDC1s by using poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with the anti-Clec9α antibody [11] eventually in combination with an NKT (α-galactosylceramide) agonist [148]. The gene discussed is PMEL; the disease is melanoma.